Information Provided By: 
Fly News Breaks for July 18, 2019
ABT
Jul 18, 2019 | 08:55 EDT
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $98 from $80 saying the company's growth story is "still going strong" following its Q2 results. The quarter is more proof that the pharma exit and medtech "double-down" was right move, Denhoy tells investors in a research note. Despite Abbott's "strong" current momentum, each product cycle is still in early innings, adds the analyst. He keeps a Buy rating on the shares.
News For ABT From the Last 2 Days
There are no results for your query ABT
